國藥控股(01099.HK)附屬與海泰新光(688677.SH)簽訂合資合作備忘錄
格隆匯12月8日丨國藥控股(01099.HK)發佈公吿,2021年12月6日,公司附屬公司國藥器械與海泰新光(688677.SH)就設立合資公司事宜簽訂《合資合作備忘錄》。根據備忘錄,國藥器械及海泰新光擬以現金出資方式按51:49的比例設立合資公司,合資公司註冊資本總額為人民幣16,000萬元。
合資公司將以醫用內窺鏡整機系統為切入點,瞄準中國醫用內窺鏡市場,建立自主品牌,迅速實現取證和銷售,逐步在中國市場佔有一定的市場份額,並同步啟動下一代技術和產品的研發和迭代,包括3D、人工智能以及其他微創外科技術和產品,打造國產醫用內窺鏡整機和微創外科領域領先企業。
公吿稱,備忘錄框架下的合資合作,將有助於公司進一步提升在醫療器械產業的一體化供應鏈服務能力,順應國家鼓勵中高端醫療器械加速進口替代的政策導向,符合集團發展醫療器械工業製造的中長期戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.